Total
0
Shares
Creso Pharma (ASX:CPH) - Chairman, Adam Blumenthal - The Market Herald
Chairman, Adam Blumenthal
Source: EverBlu Capital
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Creso Pharma (CPH) has expanded its agreement with Route2 Pharm to allow its products to be distributed in Ecuador
  • Route2 is a subsidiary of Route2Health which has over 30 years of experience producing and distributing herbal remedies and dietary supplements
  • Ecuador is an ideal market to enter into as it recently passed legislation for the production and consumption of cannabis for medicinal treatment
  • The Latin America and Caribbean cannabis market has 655 million users and is expected to be valued at over US$300 million (around A$391 million) by 2024
  • Creso Pharma is up 1.39 per cent and shares are trading at 18.3 cents

Creso Pharma (CPH) has expanded its agreement with Route2 Pharm to allow its products to be distributed in Ecuador.

Route2 Pharm is a subsidiary of Route2Health which has over 30 years of experience in the pharmaceutical science industry.

It focusses on producing and distributing herbal remedies and dietary supplements worldwide.

"Our company has thirty years' experience of successfully bringing products to market," Route2 Managing Director Shahnawaz Baig said.

"Our collaboration with Creso is progressing very well and we are excited to continue to expand this valuable partnership to include further new markets," he added.

Ecuador is an ideal market to enter into as it recently passed legislation to approve the production, use, consumption and commercialisation of cannabis for medicinal and therapeutic treatment.

The Latin America and Caribbean cannabis market has 655 million users and is expected to be valued over US$300 million (around A$391 million) by 2024.

Creso Pharma's current portfolio consists of 13 products, eight of which have been commercialised and are already generating revenue.

"The evolving regulations in Ecuador and the broader Latin American and Caribbean region present a tremendous opportunity for both our human and animal products," Non-Executive Chairman Adam Blumenthal commented.

"We are witnessing strong uptake across our entire product suite and this agreement provides further evidence of the considerable potential that the company has in established and emerging markets alike," he added.

Creso Pharma is up 1.39 per cent and shares are trading at 18.3 cents at 12:39 pm AEST.

CPH by the numbers
More From The Market Herald
Rhythm Biosciences (ASX:RHY) brings ColoSTAT trial to Queensland

" Proteomics International Laboratories (ASX:PIQ) to collaborate for world’s first endometriosis test

Proteomics International Laboratories (PIQ) has penned a research agreement to develop a non-invasive test for endometriosis.
ResApp Health (ASX:RAP) - CEO & Managing Director, Dr Tony Keating - The Market Herald

" ResApp Health (ASX:RAP) secures two deals to integrate its diagnostic test

ResApp Health (RAP) has secured two new agreements for its smartphone-based acute respiratory diagnostic test.
Paradigm Biopharmaceuticals (ASX:PAR) - Chairman & CEO, Paul Rennie - The Market Herald

" FDA requests further clarification from Paradigm Biopharmaceuticals (ASX:PAR)

The US Food and Drug Administration has requested further clarification from Paradigm Biopharmaceuticals (PAR) for its Investigational New Drug (IND) application.
Patrys (ASX:PAB) - CEO and Managing Director, Dr James Campbell - The Market Herald

" Patrys’ (ASX:PAB) clinical trials pushed back

Patrys’ (PAB) planned PAT-DX1 clinical trial will be postponed for up to six months due to global manufacturing and supply chain delays.